Healthcare | May 08, 2026
Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
Good momentum in commercial CDMO business
Expands manufacturing push & locks in major growth deals
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Subscribe To Our Newsletter & Stay Updated
